Will Madrigal’s New siRNA MASH Candidate Shift Madrigal Pharmaceuticals' (MDGL) Rezdiffra-Centric Narrative

Simply Wall St.07-04

In late June and early July 2026, Suzhou Ribo Life Science announced it had reached the first candidate drug nomination milestone in its siRNA partnership with Madrigal Pharmaceuticals to develop RNA ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648695066?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-04 12:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648695066","market":"sg","top_or_hot":-1,"title":"Will Madrigal’s New siRNA MASH Candidate Shift Madrigal Pharmaceuticals' (MDGL) Rezdiffra-Centric Narrative","media":"Simply Wall St.","content":"<div>\n<p>In late June and early July 2026, Suzhou Ribo Life Science announced it had reached the first candidate drug nomination milestone in its siRNA partnership with Madrigal Pharmaceuticals to develop RNA ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/will-madrigals-new-sirna-mash-candidate-shift-madrigal-pharm\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Madrigal’s New siRNA MASH Candidate Shift Madrigal Pharmaceuticals' (MDGL) Rezdiffra-Centric Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Madrigal’s New siRNA MASH Candidate Shift Madrigal Pharmaceuticals' (MDGL) Rezdiffra-Centric Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-04 12:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/will-madrigals-new-sirna-mash-candidate-shift-madrigal-pharm><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late June and early July 2026, Suzhou Ribo Life Science announced it had reached the first candidate drug nomination milestone in its siRNA partnership with Madrigal Pharmaceuticals to develop RNA ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/will-madrigals-new-sirna-mash-candidate-shift-madrigal-pharm\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIPO","symbol_name":"Defiance AI and Power Infrastructure ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/will-madrigals-new-sirna-mash-candidate-shift-madrigal-pharm","article_id":"2648695066","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/will-madrigals-new-sirna-mash-candidate-shift-madrigal-pharm","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2648695066","pubTimestamp":1783139182,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late June and early July 2026, Suzhou Ribo Life Science announced it had reached the first candidate drug nomination milestone in its siRNA partnership with Madrigal Pharmaceuticals to develop RNA therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), triggering the start of IND-enabling studies for future clinical trials.\nThis progress adds an RNA-based approach to Madrigal’s largely Rezdiffra-focused pipeline, potentially broadening its toolkit for addressing a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AIPO":"Defiance AI and Power Infrastructure ETF","BK4139":"生物科技","MDGL":"Madrigal Pharmaceuticals, Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Madrigal的新siRNA MASH候选药物是否会改变Madrigal Pharmaceuticals(MDGL)以Rezdiffra为中心的叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1.5,"AIPO":0.61},"content_text":"In late June and early July 2026, Suzhou Ribo Life Science announced it had reached the first candidate drug nomination milestone in its siRNA partnership with Madrigal Pharmaceuticals to develop RNA therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), triggering the start of IND-enabling studies for future clinical trials. This progress adds an RNA-based approach to Madrigal’s largely Rezdiffra-focused pipeline, potentially broadening its toolkit for addressing a widespread liver disease with significant unmet medical need. We’ll now examine how adding an siRNA MASH candidate to Madrigal’s pipeline might influence its largely Rezdiffra-centric investment narrative. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.AdvertisementMadrigal Pharmaceuticals Investment Narrative RecapMadrigal is largely a one-drug story built around Rezdiffra, so the near term still turns on execution in MASH and ongoing outcomes data. The new siRNA milestone with Suzhou Ribo modestly broadens the pipeline but does not change that the key catalyst remains Rezdiffra’s clinical and commercial progress, while heavy R&D and SG&A spending and continued losses are the biggest near term business risks. Among recent developments, Madrigal’s inclusion in the Russell 1000 and Russell 1000 Growth indices in late June 2026 stands out. This index migration reflects its larger market footprint and can influence trading volumes and ownership mix, which matters as investors weigh Rezdiffra’s upcoming data and the early, higher risk siRNA program that has just entered IND-enabling studies. Yet investors should also recognize the risk that, even with new RNA assets, Madrigal’s dependence on Rezdiffra leaves them exposed if... Read the full narrative on Madrigal Pharmaceuticals (it's free!)Madrigal Pharmaceuticals' narrative projects $3.2 billion revenue and $935.6 million earnings by 2029. This requires 42.0% yearly revenue growth and about a $1.25 billion earnings increase from -$309.4 million today.Uncover how Madrigal Pharmaceuticals' forecasts yield a $678.71 fair value, a 29% upside to its current price.Exploring Other PerspectivesMDGL 1-Year Stock Price Chart Before this siRNA news, the most bullish analysts were assuming Madrigal could reach about US$3.6 billion in revenue and US$1.5 billion in earnings by 2028, a far more optimistic path than the baseline view. You should expect those optimistic and more cautious narratives to evolve as Rezdiffra matures and the new RNA program begins to generate its own data.Explore 6 other fair value estimates on Madrigal Pharmaceuticals - why the stock might be worth 13% less than the current price!Form Your Own VerdictDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Madrigal Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Madrigal Pharmaceuticals' overall financial health at a glance.Ready For A Different Approach?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.Uncover the next big thing with 20 elite penny stocks that balance risk and reward.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648695066","isCrawlerRequest":true}